Vascular mediators in the injured liver

Hepatology

Volumn 37, Issue 1, 2003, Pages 4-12

  Rockey, Don C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; CARBON MONOXIDE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE; PRAZOSIN; PROPRANOLOL; PROSTAGLANDIN; VASOACTIVE AGENT;

BLOOD FLOW VELOCITY; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CYTOTOXICITY; ENDOTHELIUM CELL; FIBROGENESIS; HOMEOSTASIS; HUMAN; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER INJURY; LIVER SINUSOID; MESENTERY BLOOD FLOW; MICROCIRCULATION; NEUROTRANSMISSION; NONHUMAN; PERIPHERAL CIRCULATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; RECEPTOR BINDING; REVIEW; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; STELLATE CELL; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; VASODILATATION; WOUND HEALING;

EID: 0037222762     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50044     Document Type: Review

References (96)

1. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, Masini E, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27.
2. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough. Hepatology 2002;35:478-491.
3. Lautt WW, Greenway CV, Legare DJ, Weisman H. Localization of intrahepatic portal vascular resistance. Am J Physiol 1986;251:G375-G381.
4. McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver 2000;20:3-7.
5. Kaneda K, Ekataksin W, Sogawa M, Matsumura A, Cho A, Kawada N. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: Localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 1998;27:735-747.
6. Sims DE. Recent advances in pericyte biology - Implications for health and disease. Can J Cardiol 1991;7:431-443.
7. Clemens MG, Zhang JX. Regulation of sinusoidal perfusion: In vivo methodology and control by endothelins. Semin Liver Dis 1999;19:383-396.
8. Oda M, Han JY, Yokomori H. Local regulators of hepatic sinusoidal microcirculation: Recent advances. Clin Hemorheol Microcirc 2000;23:85-94.
9. Ekataksin W, Kaneda K. Liver microvascular architecture: An insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999;19: 359-382.
10. Zhang JX, Pegoli WJ, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994;266:G624-G632.
11. Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, Ishimura Y. Carbon monoxide: An endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995;96:2431-2437.
12. Okumura S, Takei Y, Kawano S, Nagano K, Masuda E, Goto M, Tsuji S, et al. Vasoactive effect of endothelin-1 on rat liver in vivo. Hepatology 1994;19:155-161.
13. Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, Giotti A, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agoniststimulated intracellular calcium transients. J Clin Invest 1992;90:642-646.
14. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993;213:815-823.
15. Rockey DC, Housset CN, Friedman SL. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993;92:1795-1804.
16. Bauer M, Paquette NC, Zhang JX, Bauer I, Pannen BH, Kleeberger SR, Clemens MG. Chronic ethanol consumption increases hepatic sinusoidal contractile response to endothelin-1 in the rat. Hepatology 1995;22:1565-1576.
17. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996;24:233-240.
18. Reinehr RM, Kubitz R, Peters-Regehr T, Bode JG, Haussinger D. Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. Hepatology 1998;28:1566-1577.
19. Yoo DS, Rockey DC. Endothelin receptor subtypes in liver injury: Upregulation and differential signaling in myofibroblast contractility [Abstract]. Hepatology 2000;32(Part 2):328A.
20. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S, Nakajima K, et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A 1988;85:6964-6967.
21. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992;13:103-108.
22. Lee ME, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T. Regulation of endothelin-1 gene expression by Fos and Jun. J Biol Chem 1991;266:19034-19039.
23. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol 1992;262:C854-C861.
24. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Nad Acad Sci U S A 1993;90:5999-6003.
25. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-485.
26. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995;270:15262-15268.
27. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 1995;270:29794-29798.
28. Hocher B, Thone-Reineke C, Bauer C, Raschack M, Neumayer HH. The paracrine endothelin system: Pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem 1997;35:175-189.
29. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14:385-399.
30. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-710.
31. Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE, Yanagisawa M. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994;79:1277-1285.
32. Appleton I, Tomlinson A, Chander CL, Willoughby DA. Effect of endothelin-1 on croton oil-induced granulation tissue in the rat. A pharmacologic and immunohistochemical study. Lab Invest 1992;67:703-710.
33. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995;44:895-899.
34. Kakugawa Y, Giaid A, Yanagisawa M, Baynash AG, Melnyk P, Rosenberg L, Duguid WP. Expression of endothelin-1 in pancreatic tissue of patients with chronic pancreatitis. J Pathol 1996;178:78-83.
35. Saleh D, Furukawa K, Tsao MS, Maghazachi A, Corrin B, Yanagisawa M, Barnes PJ, et al. Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: Possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187193.
36. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-1778.
37. Moller S, Emmeluth C, Henriksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 1993;19:285-290.
38. Trevisani F, Colantoni A, Gerbes AL, Gulberg V, Sica G, Caraceni P, De Notariis S, et al. Daily profile of plasma endothelin-1 and -3 in pre-ascitic cirrhosis: Relationships with the arterial pressure and renal function. J Hepatol 1997;26:808-815.
39. Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, Tosti-Guerra C, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-548.
40. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996;58:55-62.
41. Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: Potential for autocrine and paracrine effects on stellate cells. Hepatology 1998;27:472-480.
42. Shao R, Yan W, Rockey DC. Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing. J Biol Chem 1999;274:3228-3234.
43. Shao R, Rockey DC. Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing. J Cell Physiol 2002;191:342-350.
44. Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: Lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci U S A 1993;90:9266-9270.
45. Gondo K, Ueno T, Sakamoto M, Sakisaka S, Sata M, Tanikawa K. The endothelin-1 binding site in rat liver tissue: Light- and electron-microscopic autoradiographic studies. Gastroenterology 1993;104:1745-1749.
46. Leivas A, Jimenez W, Bruix J, Boix L, Bosch J, Arroyo V, Rivera F, et al. Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis: Relationship with hepatic hemodynamics. J Vasc Res 1998;35:186-193.
47. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol 1997;79:9-11.
48. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-1156.
49. Bataller R, Gines P, Lora J, Sole M, Nicolas JM, Jimenez W, Arroyo V, et al. Evidence for a local renin-angiotensin system in human liver: Expression in activated hepatic stellate cells [Abstract]. Hepatology 2001;34(Part 2):399A.
50. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
51. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991;351:714-718.
52. Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci U S A 1992;89:6711-6715.
53. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: Molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A 1992;89:6348-6352.
54. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol 1995;269:H550-H555.
55. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997;272:25437-25440.
56. Feron O, Saldana F, Michel JB, Michel T. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 1998;273:3125-3128.
57. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999;103:897905.
58. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399:597-601.
59. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-242.
60. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994;267:G416-G422.
61. Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997;100:2923-2930.
62. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-931.
63. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-351.
64. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-1228.
65. Wakabayashi Y, Takamiya R, Mizuki A, Kyokane T, Goda N, Yamaguchi T, Takeoka S, et al. Carbon monoxide overproduced by heme oxygenase-1 causes a reduction of vascular resistance in perfused rat liver. Am J Physiol 1999;277:G1088-G1096.
66. Makino N, Suematsu M, Sugiura Y, Morikawa H, Shiomi S, Goda N, Sano T, et al. Altered expression of heme oxygenase-1 in the livers of patients with portal hypertensive diseases. Hepatology 2001;33:32-42.
67. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-337.
68. Gandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem 1990;265:17432-17435.
69. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995;95:1199-1206.
70. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: Role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571-581.
71. Kawada N, Klein H, Decker K. Eicosanoid-mediated contractility of hepatic stellate cells. Biochem J 1992;285:367-371.
72. Graupera M, Garcia-Pagan JC, Peralta C, Abraldes JG Gomez G, Bragulat M, Bosch J, et al. Role of nitric oxide and cyclooxygenase products in the hyperesponse to methoxamine in cirrhotic rat liver [Abstract]. Hepatology 2001;34(Part 2):286A.
73. Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther 1988;244:283-289.
74. Bataller R, Nicolas JM, Gines P, Esteve A, Nieves Gorbig M, GarciaRamallo E, Pinzani M, et al. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Gastroenterology 1997;113:615-624.
75. Gorbig MN, Gines P, Bataller R, Nicolas JM, Garcia-Ramallo E, Tobias E, Titos E, et al. Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology 1999;30:501-509.
76. Gorbig MN, Gines P, Bataller R, Nicolas JM, Garcia-Ramallo E, Cejudo P, Sancho-Bru P, et al. Human hepatic stellate cells secrete adrenomedullin: Potential autocrine factor in the regulation of cell contractility. J Hepatol 2001;34:222-229.
77. Reynaert H, Vaeyens F, Qin H, Hellemans K, Chatterjee N, Winand D, Quartier E, et al. Somatostatin suppresses endothelin-1-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1. Gastroenterology 2001;121:915-930.
78. Gandhi CR, Nemoto EM, Watkins SC, Subbotin VM. An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride- induced acute liver injury and portal hypertension in rats. Liver 1998;18:39-48.
79. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000;105:741-748.
80. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001;98:8897-8902.
81. Albillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, Iborra J, et al. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995;109:1257-1265.
82. Lee WC, Lin HC, Yang YY, Hou MC, Lee FY, Chang FY, Lee SD. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis. Am J Gastroenterol 2001;96:1210-1216.
83. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999;29:334-339.
84. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-395.
85. Gonzalez-Abraldes J, Albillos A, Banares R, Del Arbol LR, Moitinho E, Rodriguez C, Gonzalez M, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-388.
86. Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996;98:1381-1388.
87. Cho JJ, Hocher B, Herbst H, Jia J, Ruehl M, Hahn EG, Riecken EO, et al. An oral endothelin A receptor antagonist blocks collagen synthesis and depostion in advanced rat liver fibrosis. Gastroenterology 2000;118:1169-1178.
88. Weber KT. Fibrosis, a common pathway to organ failure: Angiotensin II and tissue repair. Semin Nephrol 1997;17:467-491.
89. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.
90. Rockey DC, Chung JJ. Regulation of inducible nitric oxide synthase and nitric oxide during hepatic injury and fibrogenesis. Am J Physiol 1997;273:G124-G130.
91. Mallat A, Fouassier L, Preaux AM, Gal CS, Raufaste D, Rosenbaum J, Dhumeaux D, et al. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest 1995;96:42-49.
92. Bauer M, Bauer I, Sonin NV, Kresge N, Baveja R, Yokoyama Y, Harding D, et al. Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver. Hepatology 2000;31:937-947.
93. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-155.
94. Dubuisson L, Desmouliere A, Decourt B, Evade L, Bedin C, Boussarie L, Barrier L, et al. Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology 2002;35:325-331.
95. Moal F, Vuillemin E, Want J, Veal N, Oberti F, Cales P. Chronic administration and hemodynamic effects of a new liver specific NO donor in bile duct ligated rats [Abstract]. Hepatology 2000;32(Part 2):186A.
96. Luo B, Abrams GA, Fallon MB. Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: Correlation with pulmonary dysfunction. J Hepatol 1998;29:571-578.